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Brain metastases affect more breast cancer patients than ever before due to increased overall patient survival
with improved molecularly targeted treatments. Approximately 25–34% of breast cancer patients develop brain
metastases in their lifetime. Due to the blood–brain barrier (BBB), the standard treatment for breast cancer brain
metastases (BCBM) is surgery, stereotactic radiosurgery (SRS) and/or whole brain radiation therapy (WBRT). At
the cost of cognitive side effects, WBRT has proven efficacy in treating brain metastases when used with local
therapies such as SRS and surgery. This review investigated the potential use of glial activation positron emission
tomography (PET) imaging for radiation treatment of BCBM. In order to put these studies into context, we
provided background on current radiation treatment approaches for BCBM, our current understanding of the
brain microenvironment, its interaction with the peripheral immune system, and alterations in the brain
microenvironment by BCBM and radiation. We summarized preclinical literature on the interactions between
glial activation and cognition and clinical studies using translocator protein (TSPO) PET to image glial activation
in the context of neurological diseases. TSPO-PET is not employed clinically in assessing and guiding cancer
therapies. However, it has gained traction in preclinical studies where glial activation was investigated from
primary brain cancer, metastases and radiation treatments. Novel glial activation PET imaging and its applica
tions in preclinical studies using breast cancer models and glial immunohistochemistry are highlighted. Lastly,
we discuss the potential clinical application of glial activation imaging to improve the therapeutic ratio of ra
diation treatments for BCBM.

1. Introduction
Early diagnosis and application of molecularly targeted therapies in
breast cancer have improved extracranial disease control and overall
survival but are associated with increased brain metastases incidence
[1]. This prompted the reappraisal of brain metastases management. A
recent review established that 25–34% of breast cancer patients will
develop brain metastases in their lifetime [2]. Historically, the treatment

of choice for breast cancer brain metastases was surgery, stereotactic
radiosurgery (SRS), and/or whole brain radiation therapy (WBRT).
WBRT is an effective treatment for micro-metastases that are not visible
radiologically and reduces intracranial failure when combined with SRS
and surgery [3]. Despite this, WBRT is commonly omitted following SRS
or surgery due to late neurocognitive side effects [4]. Irradiating the
brain, activates glial cells, initiates inflammation, and causes tissue
damage. When inflammation persists and becomes chronic, it can
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contribute to cognitive decline [5].
The effect of radiation on tumors is widely known; however, the
immune system’s vital role in the efficacy of radiation therapy is com
plex and multifaceted. Besides the DNA damage induced by radiation,
the immune system response to the damage and cancer plays a key role
in tumor cell death. This interaction is further complicated in cancers
within the central nervous system (CNS), such as cancers that have
metastasized in the brain with its immune privilege status as reviewed
recently [6,7]. To understand the immune system’s response to radio
therapy and brain metastases, an intimate knowledge of brain micro
environment and neuroinflammation is required. Of particular interest
are glial cells, specifically microglia, the resident CNS parenchymal
macrophages forming the innate immune response in the brain. Micro
glia are one of the first responders to damage in the brain and are
responsible for inducing inflammation. The connection between acti
vated glial cells, neuroinflammation, and cognition is well studied in
neurological disease but less common for radiation and cancer [8,9].
Positron emission tomography (PET) with novel translocator protein
(TSPO) radiotracers have been used to assess neuroinflammation
through glial activation. Imaging glial activation from radiation and
cancer has the potential to improve brain metastases prevention and
management. Herein, we will review the connection between glial
activation and cognition with a focus on the neuroinflammatory
response. We will first consider the effects of radiation and cancer on
glial activation before discussing the current and potential use of TSPOPET imaging.

3. Results
3.1 Breast cancer brain metastases radiotherapy management strategies
Metastatic treatment is often approached differently from primary
treatment to prolong the patient’s life, palliate symptoms, and delay
disease progression. However, if breast cancer patients only have oli
gometastatic disease in the brain without active extracranial disease,
this may prompt reconsiderations of treatment goals [10]. This is
especially true in the era of effective targeted treatments for estrogen
(ER), progesterone (PR) and/or human epidermal growth factor (HER2)
positive cancers. Typically, local therapies, i.e., surgery and radiation,
are used to treat BCBM since the blood–brain barrier (BBB) prevents
penetration of antibodies into brain such as those targeting HER2. Un
like luminal A, B, and HER2 + breast cancers that are driven by ER,
progesterone PR and HER2, respectively, triple negative breast cancers
(TNBC) do not have these receptors. This limits treatment options for
TNBC, making it the most aggressive type of breast cancer that often
results in brain metastases [11]. SRS delivering a high dose in a small
number of fractions (i.e., 18–24 Gy/1, 27 Gy/3, or 35 Gy/5) to visible
growths is a standard treatment for BCBM [12]. It is recommended for
patients with up to four brain metastases, with local tumor control rates
between 90 and 95% [13–16]. WBRT may follow SRS to improve brain
metastases’ regional control but at the expense of neurocognitive side
effects [3,17,18].
Brown et al. [18] investigated the effect of SRS with and without
WBRT on patients’ cognitive function with one to three brain metastases
in a randomized clinical trial. The brain metastases were from different
types of cancer, including lung, breast, and melanoma. At the three
month assessment, SRS alone was found to have less cognition deteri
oration (40/63 patients [63.5%]) compared to SRS with WBRT (44/48
patients [91.7%]) [18]. However, SRS alone had a shorter time to
intracranial failure and lower intracranial tumor control rates (79/105
patients [75.3%]) compared to SRS with WBRT (89/95 patients
[93.7%]). While the addition of WBRT significantly improves intracra
nial tumor control, there is a significant increase in cognitive deterio
ration. In patients surviving longer than one year, cognitive
deterioration incidence was lower for SRS alone at three months (5/11
patients [45.5%] vs. 16/17 patients [94.1%]) and 12 months (6/10
patients [60%] vs. 17/18 patients [94.41%]) compared to SRS with
WBRT [18]. WBRT still has its place in BCBM treatment for patients not
eligible for surgery or SRS. This patient group typically has a median
survival of approximately three months and typically do not live longer
than 16 months. The onset of long-term cognitive deterioration is not a
significant concern, as patients receive palliative WBRT to alleviate
symptoms, temporarily halt brain metastases growth and improve
neurological deficits in the short term to improve their quality of life
[19–21].
Hippocampal sparing (HS), an advanced radiation therapy tech
nique, is used to reduce the cognition deficits associated with WBRT.
The avoidance of hippocampal structures aims to delay or minimize
onset and/or severity of cognitive decline while attaining intracranial
control of cancer. The hippocampus is responsible for the learning,
consolidation, and retrieval of information and is critical for forming
new memories [22]. The hippocampus is centrally located in the brain
and requires intensity modulated radiotherapy or volumetric modulated
arc therapy techniques to avoid it. In a phase II randomized trial, Yang
et al. [23] investigated whether HS-WBRT preserves neurocognition in
brain metastases patients. Patients who received HS-WBRT of 30 Gy in
10 fractions were found to have better memory preservation six months
post-irradiation than conventional WBRT. However, no differences were
evident between HS and conformal groups for verbal fluency and ex
ecutive function [23].

2. Methods and materials
This review begins with a brief summary of the current radiotherapy
treatment approaches for breast cancer brain metastases (BCBM) (3.1).
This is followed by a review of the current understanding of the brain
microenvironment including the role of microglia in neuroinflammation
(3.2), and the interactions of the brain immune responses with the pe
ripheral immune system (3.3). Alterations in the brain microenviron
ment from the presence of BCBM and radiation are then discussed (3.4,
3.5). We then review the connection between glial activation and
cognitive decline with clinical and preclinical studies (3.6). In the pre
clinical studies, we highlighted studies of glial activation caused by ra
diation treatment with glial immunohistochemistry or glial activation
PET imaging, as well as studies that specifically employed breast cancer
animal models. Lastly, we discuss the potential clinical application of
glial activation imaging to improve the therapeutic ratio of radiation
treatments for BCBM.
In the present review, the literature search was performed using the
PubMed database with search terms specific to the sections. Articles
were identified in the search using the terms: 1) “breast cancer brain
metastases” AND “radiation/radiation therapy” AND “microenviron
ment”, 2) “immune privilege” AND “neuroinflammation”, 3) “glial
activation” AND “cognition” AND “TSPO”, 4) “TSPO-PET” AND “radi
ation therapy/radiation” AND “brain metastases”. Relevant articles
referenced in the identified articles were also included. The overall
search identified a total of 139 articles, which were manually screened
to include articles that reported or reviewed neuroinflammation in the
brain, the connection between glial activation and cognition, or glial
activation assessment in BCBM. Only neurological studies that reported
on clinical assessment using TSPO-PET were included. This left a total of
104 articles for abstract review. After abstracts were reviewed, 53
studies met the inclusion criteria and were reviewed with full text. From
the full-text review, an additional 35 studies were added that were
referenced in the relevant articles, for a total of 88 articles discussed in
the following sections.
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3.2. The brain microenvironment and neuroinflammation: Background

nucleated cells express MHC class I molecules, and they present on the
cell surface both normal self-antigens and foreign antigens (e.g., from
viruses) found in the cytosol. Activated microglia can express MHC class
I and II molecules together with co-stimulatory molecules similar to
professional APCs. Antigens presented by MHC class I molecules are
recognized by cytotoxic CD8+ T-cells, while CD4 + helper T-cells
recognize MHC II. Antigen presentation by APCs triggers an adaptive Tcell-based immune response.
Activated macrophages in simple sense can go from M1 (pro-in
flammatory, tissue repair) to M2 (inflammation resolution, phagocy
totic) polarization, in actuality, there is a spectrum of behaviour that
spans from M1-like to M2-like [27]. The microglia’s phenotype, i.e., M1
or M2, is linked to the brain microenvironment, determined by the
presence and quantity of cytokines and chemokines. Microglia express
an M1 phenotype in a pro-inflammatory environment when cytokines
and chemokines are in abundance. The resultant microglia activation
comes from various stimulating factors including IFN-γ and lipopoly
saccharides that polarise toward the production of pro-inflammatory
cytokines, such as tumor necrosis factor (TNF), interleukin-1β (IL-1β),
IL-6, IL-12, IL-18, and IL-23 [28]. Pro-inflammatory chemokines
secreted by activated microglia include CXCL-8, CCL2, CCL3, CCL4,
CCL5, CCL11, and CXCL10, with an extensive list shown in Fig. 1 [29].
Activated M1 microglia can be identified by increased surface marker
expression of CD40 and CD86 (also known as B7-2 or T-lymphocyte
activation antigen) that are responsible for IL-2 secretion and immune
cell proliferation [30]. Other surface markers promoting inflammation
include CD16, CD32, and inducible nitric oxide synthase (iNOS). The
majority of pro-inflammatory cytokines are produced by activated
microglia, playing an integral role in the subsequent activation of
downstream pathways.
Alternatively, microglia can create an anti-inflammatory microen
vironment when they changed polarization to an M2 phenotype.
Microglia in the M2 polarization induce an immunosuppressive
response, helping to stop inflammation and restore homeostasis to the
surrounding microenvironment. Identification of activated M2 micro
glia is through CD206 and CD163 surface markers, cytokines (IL-1

The brain microenvironment plays a vital role in maintaining and
protecting brain function, including preventing cancer metastasis in the
brain. Cancer cells have to adapt to the brain microenvironment to
survive, develop and progress to metastases. The brain is primarily
composed of neurons, glial cells, and endothelial cells. Glial cells are
responsible for maintaining tissue homeostasis. There are three types of
glial cells: oligodendrocytes, astrocytes, and microglia, accounting for
approximately 75%, 20%, and 5% of the glial cells in the gray matter of
the human cerebral cortex, respectively [24]. Despite being a minor
component, microglia are the resident CNS parenchymal macrophages
forming the innate immune response in the brain. In the CNS, activation
of the microglia releases inflammatory mediators triggering immune
responses and altering the brain’s microenvironment.
Inflammation is an important biological response governed by the
immune system. Maintaining homeostasis and identifying harmful
stimuli, including pathogens, damaged cells, or irritants by the body,
will induce an inflammatory response. Inflammation in the brain differs
from peripheral inflammation since fewer antibodies and leukocytes are
present. The BBB is mainly responsible for reduced leukocytes presence,
although inflammation can increase immune cell traffic across the BBB
and leukocyte recruitment [25]. Neuroinflammation and subsequent
immune reactions are cultivated and regulated by simultaneous
communication and response between the immune system and the CNS
[26].
3.2.1. The role of microglia in neuroinflammation
Homeostasis disturbances activate microglia as part of the innate
immune response. Microglia and astrocytes are not considered profes
sional antigen presenting cells (APCs) because they do not acquire APC
ability in the absence of co-stimulatory cytokine molecules. Professional
APCs such as dendritic cells, circulating macrophages, and B cells
phagocyte extracellular proteins, and the resulting peptide fragments
from proteins are presented by the major histocompatibility complex
(MHC) class II molecules on the cell surface. On the other hand, all

Fig. 1. Diagram of the cascading relationship of radiation induced glial activation to cognitive impairment. Created with biorender.com.
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receptor antagonist (IL-1Ra), IL-4, IL-10, IL-13, and transforming
growth factor (TGF-β)) and chemokines (CCL2, CCL22, CCL17, and
CCL24) [30]. This is accompanied by increased secretion of antibodies
and the release of several protective and trophic factors, enhancing
phagocytosis of pathogens and supporting neuronal growth, inflamma
tion regulation, and repair. The ratio of markers present can be used in
tissue or culture to determine which phenotype is predominant.

cellular infiltration, activated and memory T-cells can cross these bar
riers by expressing integrins, adhesion molecules, and chemokine re
ceptors [39]. Activated T-cells can use various routes to reach distinct
areas of the CNS. For example, certain T-cells can cross the BBB into
perivascular space and fluid-filled spaces in the brain surrounding
perforating vessels, and activated T-cells can cross the BBB and cerebral
spinal fluid barrier to enter the brain subarachnoid space [39]. Once Tcells enter the brain, they can interact with microglia in the brain
parenchyma.

3.3. The central nervous system and immune privilege
The BBB is a physical and biological barrier with specialized proteins
accountable for transport across the membrane. For instance, a
multidrug-resistant protein actively pumps out drugs that crossed into
the brain, e.g., chemotherapy drugs. Studies reported that CNS tissues
lacked lymphatic vessels [31–33]. These led to the belief that the CNS is
isolated by the BBB and does not interact with the peripheral immune
cells, giving it the status of being one of the immune-privileged sites in
the human body [33]. However, it was demonstrated recently that the
CNS has immune competency and active interaction with peripheral
immune cells (reviewed in [34]).
The lymphatic system is an essential component of the immune
system consisting of a network of lymph nodes connected by lymphatic
vessels facilitating the defense response. Until recently, the link between
the CNS and the lymphatic pathway was unknown. In 2015, Louveau
et al. [6] and Aspelund et al. [7] reported that lymphatic vessels line the
dural sinuses and connect to cervical lymph nodes, with the capability of
transporting immune cells from the cerebrospinal fluid [6,7]. The sinusassociated lymphatic vessels were discovered to be strongly associated
with T-lymphocytes and suggested responsibility for providing the
means for peripheral immune cells to leave the cranium [6]. The
lymphatic pathway enables soluble antigens present in the brain pa
renchyma to drain into the cervical lymph nodes. Thus, the BBB main
tains the brain parenchyma’s immune privilege status, while the
lymphatic pathway enables it to be an active participant in the immune
surveillance of the CNS. Dendritic cells in the lymphatics will also take
up antigens from the CNS and bring them into the lymph nodes. The
dendritic cells are present in the brain’s meninges lining and choroid
plexus of the ventricles but are not found throughout the brain paren
chymal. Thus, the CNS has a restricted capacity to transport antigens to
lymph nodes and induce T-cell activation [35]. When the innate immune
response in the CNS is insufficient, antigen introduction in the lymph
nodes is necessary for the lymphatic system to initiate adaptive
immunity.
T-cells activated by pathogens outside of the CNS can detect anti
genic targets within the CNS. Medawar demonstrated this phenomenon
experimentally in the late 1940s [36,37]. The slow rejection rate of
foreign tissue grafts transplanted within the CNS compared to rapid
rejection seen in skin grafts showed immune privilege. Interestingly, the
CNS rejection response mimicked the skin grafts response when trans
plantation of skin grafts was before the CNS grafts. Furthermore, skin
graft transplanted after the CNS graft accelerated its rejection response.
Thus, these studies showed the ability of peripheral identified foreign
antigens to initiate an additional immune response within the CNS
despite its privileged immune status.
Communication between immunity in the brain and body in a gen
eral sense is a two-way process and has the potential to allow peripheral
cells to join in the response. The origin and recruitment of immune cells
from stimulus within the CNS can be extended to peripheral cells, as
signals can be sent to peripheral cells to initiate a reaction. CNS
inflammation can be initiated in two ways: 1) by antigens derived from
the CNS that result from direct damage to the brain parenchyma or 2)
from a source originating outside of the CNS. In both cases, myelinspecific T-cells are primed and then entered the brain (reviewed in
[38]). Inducing a T-cell response in the CNS requires antigens to drain
into the cervical lymph nodes and T-cells to enter the CNS.
Although the CNS has many barriers that protect the brain from

3.4 Changes in the brain microenvironment from brain metastases
The interaction between the brain microenvironment and metastatic
cells impacts tumor progression and survival [40,41]. Doron et al. [42]
reviewed the role of various immune cells in the brain tumor microen
vironment (TME) and their contribution to inflammation in influencing
disease progression. Pathogen invasion or tissue damage trigger damage
signals that initiate inflammation. Surrounding microglia and astrocytes
are rapidly activated, acting as first responders. Peripheral T-cells
become involved if microglia and astrocytes have not managed to con
trol the invasion or damage, inducing widespread neuroinflammation.
Changes in the brain microenvironment from tissue damage and dys
regulation are similar to changes introduced by metastatic growth in the
brain, including the induction of neuroinflammation [42,43]. The pos
itive feedback loop generated with activated microglia and reactive
astrocytes in response to damage signals can initiate colonization of
cancer cells [44]. The changes and reactions occurring in the brain
microenvironment suggest that metastatic cells take over the tissue
damage response. Understanding the role of neuroinflammation could
further uncover the inner workings of brain metastases development
[43,45].
Microglia polarization plays an essential role in the progression of
tumors. Typically, M1 cells are produced in non-malignant tumors to
induce tumor death, as the hindrance of cancer stem cells’ sphereforming capacity will inhibit tumor growth [46]. Komohara et al. [47]
investigated the role of M1 and M2 cells in tumor proliferation and
found that M2 cells’ expression of STAT3 is key to tumor progression.
Furthermore, the TME of brain metastases is different among primary
cancers (reviewed in[48]).
Primary breast cancer cells that have spread to the brain are met by
various immune cells on arrival, including microglia. Cytokines, che
mokines, and neurotoxic agents secreted by microglia directly or indi
rectly play a role in immunosuppression, angiogenesis, tumor
proliferation, invasion, and neuroinflammation [49,50]. Prolonged
neuroinflammation can exacerbate these effects through the continuous
cycle of molecule secretion and activation of microglia. Commonly,
activated microglia will surround lesions in the brain, and their inhibi
tion has demonstrated reduced tumor proliferation [51]. Reactive as
trocytes have also been found in the vicinity of brain lesions and
promote cancer growth through the secretion of cytokine, growth fac
tors, and enzymes. Lorger et al. [52] examined the brain microenvi
ronment during the first stages of hematogenous BCBM in an animal
model with the involvement of different resident brain cells. In vivo
experiments using mouse models with MDA-MB-435, MDA-MB-231,
MDA-MB-231/brain, 4 T1, and MCF-7 cells investigated breast cancer
cell arrest and extravasation into the brain parenchyma. MDA-MB-435,
MDA-MB-231/brain, and 4 T1 cells were found to provide better models
for examining the earliest events involved with breast cancer cells
infiltration into the brain and were the only cell types to develop lesions
consistently. Regardless of the host’s immune state and tumor cell
model, breast cancer cells were found arrested in the microvasculature
of the mouse brain and were in the process of extravasation from day
three onward. Cancer cell arrest, extravasation, and invasion of the brain
parenchyma often result in concentrated activated microglia and reac
tive astrocytes [52]. However, the authors mentioned that the functional
contributions of the different glial populations remain unknown.
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Brain tumors, primary or metastatic, alter the brain microenviron
ment. For instance, the BBB integrity can degrade from tumor angio
genesis [53]. Increased angiogenic growth factors such as vascular
endothelial growth factor (VEGF) that disrupt endothelial permeability
by promoting endocytosis of endothelial cell adhesion molecule VEcadherin, leading to increased immune cell infiltration from the pe
ripheral circulation [54].
Tumors take advantage of macrophage polarization, creating a
microenvironment conducive to growth. Tumor-associated macro
phages (TAMs) are among the main immune cells that induce an
immunosuppressive TME and significantly contribute to tumor cell in
vasion, development, and growth (reviewed in [55]). The TME is
responsible for M2 polarization of TAMs and its release of factors,
including IL-4, IL-10, IL-13, and TGF-β [56]. M2 macrophage polariza
tion changes antigen presentation, receptor expression, and cytokine
production, aligning with immunoinhibitory, pro-tumor, and angio
genic effects when the tumor establishes itself [57]. This holds for most
tumors, including breast cancer. Furthermore, TAM rich microenviron
ments suggest aggressive tumor progression with increased metastatic
potential.
Jeong et al. [58] evaluated the relationship between marker
expression in breast cancer and the presence of TAMs. Examination of
367 patients with invasive breast cancer revealed a high degree of TAM
infiltration with high histological grade, greater tumor size, ER nega
tivity, PR negativity, and Ki-67 proliferation index. TNBC is hormone
receptor negative and associated with a poor prognosis resulting from
aggressive behavior and lack of targets for treatment. In the context of
immunotherapy, the TAM phenotype can play a role in the outcome
[59].

irradiation leading to cognitive impairments and morphological
changes, including vascular abnormalities, demyelination, white matter
necrosis [60,61,68,69]. However, cognition impairments can also occur
with no detectable morphological changes [70]. Cognitive impairments
manifest with varying severity in memory, learning, critical thinking,
and IQ performance [70].
3.6 The connection between glial activation & cognition: Clinical TSPOPET and preclinical studies
In the brain’s microenvironment, the initial pro-inflammatory
response to damage must be countered with an anti-inflammatory
response to restore equilibrium and maintain homeostasis. TSPO-18
kDa, previously known as the peripheral benzodiazepine receptor, is a
protein located on the outer mitochondrial membrane within glial cells.
Under normal physiological conditions TSPO expression in the brain is
low, but in response to glial activation, it is upregulated on activated
microglia and reactive astrocytes. Several TSPO-PET radiotracers have
been developed to visualize TSPO biodistribution and expression, with
development efforts focused on improving pharmacokinetics and image
quality. TSPO radiotracers are designed with a TSPO ligand with high
binding affinity and selectivity. Zhang et al. [71] provided a compre
hensive review of recent TSPO-PET radiotracers developments and
neuroimaging. The precise mechanism regarding the elevated expres
sion of TSPO in glial cells is not fully understood. However, the transi
tion of microglia from resting to active state and glial proliferation
resulting from tissue damage has demonstrated a significant increase in
TSPO expression [72,73]. Below, we will begin by reviewing the
connection between glial activation using TSPO-PET imaging and
cognition in the clinical setting. This is followed by preclinical studies
linking cognition with glial activation using TSPO-PET imaging or
immunohistochemistry.

3.5. Radiation induced changes in the brain microenvironment
Many radiation-induced alterations in the brain contribute to proinflammatory immune responses. These include DNA damage, cell
death, senescence, hypoxia, cellular stress, tumor antigens, damageassociated molecular patterns (DAMPs), and neoantigens (reviewed in
[60]). Low-grade inflammation is needed to clear toxins and damaged
cells, protect and heal tissue [61]. However, chronic inflammation and
the resultant cytokine storm (i.e., persistently elevated proinflammatory
cytokines, chemokines, and neurotoxic agents) promote and sustain M1
activation and pro-inflammatory molecule production [62]. Cytokine
storms are associated with immune cell hyperactivity, which produces
reactive oxygen species (ROS) and reactive nitrogen species (RNS) that
are toxic to cells, create a destructive environment, and induce patho
logical consequences, including neuronal damage and cell death
[63–66]. The resultant neuronal damage and cell death initiate more
microglial activation, sustaining a proinflammatory environment [44].
Studies have looked into suppressing this immune response by inhibiting
CD4+ T-cell activation, which is necessary for cells to enter the brain as a
result of the inflammatory response (reviewed in [67]). Furthermore,
chronic inflammation is found to be a major contributor to cognitive
decline [68,69]. The assessment of glial activation duration and severity
associated with neuroinflammation will help understand the relation
ship to cognitive side effects. The cascading relationship of the neuro
inflammatory response and detrimental impact on cognition is
illustrated in Fig. 1. The damage/injury to the brain from radiation in
cludes acute, early delayed, and late injuries. Acute injuries resolve
within hours to days, with symptoms such as headaches and drowsiness.
Early delayed injuries resolve within a few weeks and do not have a
lasting effect on cognition, including short-term memory loss and
decreased attentiveness associated with WBRT stemming from transient
demyelination [70]. Late brain injuries are more concerning and can
significantly affect the quality and quantity of a patient’s life. Late in
juries from cranial irradiation are typically irreversible, occur more than
six months later. Several publications have reviewed the immune re
actions and subsequent inflammation in the brain induced from

3.6.1. TSPO-PET imaging assessment in clinical studies
Neuroinflammation assessment with TSPO-PET has been used in
clinical studies for neurodegenerative diseases, including MS, Alz
heimer’s disease, and Parkinson’s disease [74–77]. Additionally, several
TSPO-PET radiotracers are approved for human imaging, including
[11C]PK11195 , [11C]PBR28, [11C]DAA1106, [18F]DPA-714, [18F]
PBR06, [18F]FEPPA and [18F]PBR111 (reviewed in [78]). Sucksdorff
et al. [76] recently investigated MS progression using TSPO-PET with
[11C]PK11195. The data collected demonstrated that increased uptake
of TSPO predicts greater clinical disability. Similar to cancer and radi
ation damage, MS progression correlates with adopting a proin
flammatory phenotype within the CNS [79]. Neurodegenerative
diseases are associated with neuroinflammation and are characterized
by microglia changes, increased cytokine abundance, oxidative stress,
and neuronal loss, resulting from the chronic nature of the disease [80].
Studies of neurodegenerative neuroinflammation imaging assessments
are more abundant than those regarding cancer and have been approved
for human use. The next logical step is to examine neuroinflammation in
response to cancer and treatment.
Research in neuroinflammation imaging has typically focused on
PET imaging with TSPO radiotracers, however, it remains challenging to
quantify and has limitations that include low-affinity binding in at least
5% of the population due to a polymorphism in the TSPO gene as well as
expression in non-glial cells (e.g. platelets, endothial cells and cancer
cells) [8,9]. Narayamaswami et al. [81] identified several alternative
neuroinflammation targets for neurodegenerative diseases, including
glycogen synthase kinase, monoamine oxidase-B, reactive oxygen spe
cies, imidazoline-2 binding sites, and cyclooxygenase. Recent promising
PET tracers also target the macrophage colony-stimulating factor 1 re
ceptor (CSF1R) [82] and triggering receptor expressed on myeloid cells
1 (TREM1) [83]. Although promising, most alternatives to TSPO-PET
have only been demonstrated in preclinical studies and have yet to be
translated to patients studies.
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imaging with [11C]PK11195 on days three and 31. Radiotracer uptake
for the whole brain was similar in all groups at day three and signifi
cantly decreased for the control and 10 Gy group at day 31, while the 25
Gy group had a similar uptake on day three and day 31, suggesting that
higher than 10 Gy dose is required to elicit a sustained activation of
microglia [92]. This supports a dose-dependent relationship with glial
activation, in line with differences in severity of tissue damage with
dose. The longitudinal study allowed for monitoring of glial activation
and provided insight into acute and late effects of radiation but lacked
immunohistochemistry confirmation.

3.6.2. Preclinical evaluations of glial activation and cognition
Typically, neuroinflammation assessment involves the evaluation of
glial activation using immunohistochemistry and medical imaging. PET
imaging with TSPO-targeted radiotracers has shown to be sensitive at
the onset of disease in clinical and preclinical studies in neurological
disease [84]. The reviewed studies include glial activation and, in turn,
inflammation arising from multiple sclerosis (MS), stroke, traumatic
brain injury, human immunodeficiency virus infection, and psychiatric
diseases, but not from radiation.
Cosenza et al. [85] performed a comprehensive immunohistochem
ical analysis of TSPO expression in the abnormal human brain. TSPO
expression was confirmed to be predominated by microglia and mac
rophages; however, activated astrocytes can also express TSPO.
Recently, Zhang et al. [86] investigated the role of microglia with
cognitive deficits in a rotenone-induced Parkinson’s disease model.
Rotenone was used to induce cognitive deficits, as demonstrated by
reduced performance in novel object recognition, passive avoidance,
and Morris water maze compared to controls. Microglia were depleted
or inactivated by a colony-stimulating factor-1 (CSF-1) receptor,
PLX3397, or minocycline. Depleted microglia reduced neuronal damage
and exhibited an ameliorated cognitive performance deficit in rotenoneinjected mice [86]. This study showed that glial activation plays a
critical role in cognitive decline in mice and adds experimental evidence
for the link between glial activation and cognitive decline.
Similarly, Acharya et al. [87] examined how the elimination of
microglia affected cognitive function following cranial irradiation in a
murine model. Microglia eliminated by CSF-1 receptor inhibition had
improved cognitive deficits in irradiated mice compared to controls,
assessed with novel object recognition and object in place exploration
tasks.
Wlodarek et al. [88] investigated radiation induced cognitive
impairment rectification in a murine model. WBRT is associated with
cognitive impairments stemming from regional neuroinflammation,
resulting in neuronal damage and microglial activation in the sur
rounding area, causing increased neuronal death and cognitive decline
from a cytokine storm [4,5,88]. However, the amount of radiation and
delivery schedule required to cause these effects is unknown. Wlodarek
et al. [88] implanted hematopoietic stem cells from young and old mice
irradiated for ten minutes at a rate of 1 Gy/min (10 Gy total, Cs-137
irradiator). Novel object recognition and open-field tests assessed the
mice’s learning and memory. Interestingly, in areas of the brain asso
ciated with learning and memory, microglia-like cells in young mice
were polarized to a reparative phenotype in irradiated mice. The selfrenewing young hematopoietic stem cells were able to enter the brain
and differentiate into anti-inflammatory microglia. The increase in antiinflammatory microglia present in the brain worked toward maintaining
homeostasis and positively affected cognition [88]. This demonstrated
the strong connection between the presence of activated microglia
activation and its subsequent neuroinflammation with cognition.
Recently, ultra-rapid “FLASH” radiation has demonstrated normal
tissue sparing compared to conventional radiation therapy at the same
dose level [89,90]. Simmons et al. [91] evaluated FLASH radiation for
its capability to mitigate neurodegeneration, neuroinflammation, and
associated cognitive impairments found with conventional delivery.
Three-month-old male C57BL6/J mice were evaluated ten weeks post
30 Gy WBRT using spatial and non-spatial object recognition and neu
roinflammation immunohistochemistry. The cohort that received
FLASH radiation had significantly less expression of microglia marker
CD68 and exhibited reduced memory impairment in object location and
novel object recognition tests than conventional radiotherapy and
showed no significant differences from the control. Reduction in
cognitive impairments could be the result of ameliorated neuro
inflammation [91].
Parente et al. [92] investigated the effect of WBRT on glial activation
and behavior in rats using TSPO-PET. Male Wistar-Unilever rats
received WBRT of 10 Gy or 25 Gy (N = 8 per group), followed by PET

3.6.3. Preclinical assessment of glial activation in breast cancer brain
metastases
In recent years, preclinical studies have begun exploring glial acti
vation associated with brain irradiation and cancer but not yet clinically
in patients. With strong evidence for the connection between glial
activation and cognitive deficits, preclinical studies have begun to
examine the contributions to glial activation and neuroinflammation,
including primary cancer [93,94], brain metastasis [95–98] and cancer
treatments [87,88,91,92].
In a mouse model of TNBC (MDA-MB-231), Smart et al. [95] found
that neuroinflammation was metastasis-drive in Female athymic nu/nu
NRC mice. Comparable levels of neuroinflammation were observed in
metastatic mice brains without and with WBRT, including fractionation
of 30 Gy in 10 fractions and a single fraction of 15 Gy, but significantly
lower to almost no neuroinflammation present in metastases free mice
brains with the same WBRT. However, the group evaluated neuro
inflammation with immunohistochemistry on day 28, had the evalua
tion timepoint been earlier, they might have seen a different relationship
since microglia is the first step in the neuroinflammatory response.
O’Brien et al. [96] used TSPO-targeted radiotracers to examine glial
activation in the early stages of brain metastasis with single-photon
emission computed tomography (SPECT). The brain metastases mouse
models used in the study involved direct injection or intracardiac in
jection of 4 T1 mammary mouse carcinoma into female BALB/c mice.
SPECT imaging of brain metastasis in both models showed TSPO upre
gulation, indicating glial activation and providing a greater imaging
target than the visible metastasis alone [96]. Interestingly, the glial
activation was different between tumor models (diffuse versus local).
The direct injection (intracerebral) model on day 14 showed reactive
astrocytes had a more robust TSPO upregulation than microglia upon
immunohistochemistry stains. In contrast, the intracardiac model
imaged on day 21 showed reactive astrocytes mainly at the tumor
periphery.
Similarly, Andreou et al. [97] examined glial activation using
immunohistochemistry and immunofluorescence in BCBM. The group
injected 4 T1-green fluorescent protein (GFP) mammary carcinoma cells
directly into the brain of female BALB/c mice and completed a 28-day
time-course study. Over the length of the study, the infiltration of
microglia/macrophages was maintained and positively correlated with
tumor burden. Both pro- and anti-inflammatory phenotypes were
evident, although the metastatic burden was ameliorated by depleting
the anti-inflammatory population with mannosylated clodronate lipo
somes. This provided evidence of the importance of glial cells’ M2 po
larization in supporting cancer growth.
In a metastatic breast cancer model, Simon et al. [98] explored the
interaction between tumors and microglia. Using intravital imaging
with an optical window implanted in Cx3cr1GFP/+ mice, they found that
MDA-MB-231 metastatic breast cancer cells impacted microglial
morphology. Multiphoton microscopy performed through the optical
window allowed for the visualization of activated microglia labeled with
GFP and breast cancer cells transduced with recombined lentivirus for
discosoma red (DSRed). Activated microglia surrounded the lesion, and
intravital brain imaging showed tumor cell infiltration and microglia
recruitment to the lesion [97]. The studies reviewed indicate microglia
have an active role in developing and progressing brain metastases and
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suggesting anti-inflammatory phenotypes may be a promising target for
therapeutic intervention.
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[33] Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration
into the central nervous system. Nat Rev Immunol 2003;3(7):569–81.
[34] Prinz M, Priller J. The role of peripheral immune cells in the CNS in steady state
and disease. Nat Neurosci 2017;20(2):136–44.
[35] Mendez-Fernandez YV, Hansen MJ, Rodriguez M, Pease LR. Anatomical and
Cellular Requirements for the Activation and Migration of Virus-Specific CD8+ T
Cells to the Brain during Theiler’s Virus Infection. J Virol 2005;79(5):3063–70.
[36] Medawar PB. Immunity to homologous grafted skin; the relationship between the
antigens of blood and skin. Br J Exp Pathol 1946;27(1):15–24.
[37] Medawar PB. Immunity to homologous grafted skin; the fate of skin homografts
transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of
the eye. Br J Exp Pathol 1948;29(1):58–69.
[38] Korn T, Kallies A. T cell responses in the central nervous system. Nat Rev Immunol
2017;17(3):179–94.
[39] Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev
Immunol 2009;9(6):393–407.
[40] Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev
Cancer 2009;9(4):239–52.
[41] Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and
metastasis. Nat Med 2013;19(11):1423–37.
[42] Doron H, Pukrop T, Erez N. A blazing landscape: Neuroinflammation shapes brain
metastasis. Cancer Res 2019;79(3):423–36.

4. Discussion
Cranial irradiation is an effective treatment for brain cancer; how
ever, the cognitive impairments can be severe, leading to the investi
gation of approaches to reduce radiation induced cognition
impairments. The connection between persistent microglial activation
and effects on deficits in cognition in neurodegenerative diseases has
been well studied (reviewed in [80]). The imaging methods used in
these studies can be applied to radiation and cancer-induced glial acti
vation to better manage patients with brain metastases and reduce
radiation-induced cognitive impairments. However, no TSPO-PET
studies look at radiation induced glial activation and its impact on
cognitive functions with glial immunohistochemistry. More preclinical
studies investigating glial activation from cancer and radiation are
needed. As TSPO-PET has shown significant promise in measuring glial
activation in the brain for neurological disease, it has the potential to
impact radiation treatments for breast cancer patients. TSPO-PET could
be used to evaluate post-irradiation glial activation (neuro
inflammation) and modify WBRT for BCBM in an effort to reduce
cognitive side effects. TSPO-PET may have very broad applications to
include other forms of cancer treatments that alter the neuro
inflammatory environment of the brain, including adjuvant or combi
nation immunotherapy and anti-inflammatory steroids such as
Dexamethasone.
The present review focuses on BCBM, because systemic treatments
have increased breast cancer patients’ overall survival, along with
incidence of brain metastases. However, the results from the studies
discussed could be applied to brain metastases originating from other
primary cancers, especially in the brain metastasis patient population
with controlled extracranial diseases and surviving long enough to
experience radiation induced neuro-toxicities. Future investigation of
the connection between radiation and cancer-induced glial activation is
an essential step toward the refinement of radiation treatment of BCBM
with the potential to minimize neurotoxicity.
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inflammatory response to solid cancer metastases in the human brain. Clin Exp
Metastasis 2013;30(1):69–81.
[46] Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 Macrophages and the
Th1/Th2 Paradigm. J Immunol 2000;164(12):6166–73.
[47] Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 antiinflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008;
216(1):15–24.
[48] Cacho-Díaz B, Garcia-Botello DR, Wegman-Ostrosky T, Reyes-Soto G, OrtizSanchez E, Herrera-Montalvo LA. Tumor microenvironment differences between
primary tumor and brain metastases. J Transl Med 2020;18(1):1–12.
[49] Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive
glia are recruited by highly proliferative brain metastases of breast cancer and
promote tumor cell colonization. Clin Exp Metastasis 2008;25(7):799–810.
[50] Markovic DS, Vinnakota K, Chirasani S, Synowitz M, Raguet H, Stock K, et al.
Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion.
Proc Natl Acad Sci U S A 2009;106(30):12530–5.
[51] Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain
microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and
glioma growth. Hum Mol Genet 2007;16(9):1098–112.
[52] Lorger M, Felding-Habermann B. Capturing changes in the brain
microenvironment during initial steps of breast cancer brain metastasis. Am J
Pathol 2010;176(6):2958–71.
[53] Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G, McCarty JH. Metastatic
brain tumors disrupt the blood-brain barrier and alter lipid metabolism by
inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep
2018;8(1):8267.
[54] Gavard J, Gutkind JS. VEGF Controls endothelial-cell permeability promoting
β-arrestin-dependent Endocytosis VE-cadherin. Nat Cell Biol 2006;8(11):1223–34.
[55] Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages:
An accomplice in solid tumor progression. J Biomed Sci 2019;26(1):78.
[56] Lee C, Jeong H, Bae Y, Shin K, Kang S, Kim H, et al. Targeting of M2-like tumorassociated macrophages with a melittin-based pro-apoptotic peptide.
J ImmunoTher Cancer 2019;7(1):147.
[57] Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in Tumor
Microenvironments and the Progression of Tumors. Clin Dev Immunol 2012;2012:
1–12.
[58] Jeong H, Hwang I, Kang SH, Shin HC, Kwon SY. Tumor-Associated Macrophages as
Potential Prognostic Biomarkers of Invasive Breast Cancer. J Breast Cancer 2019;
22(1):38–51.
[59] Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M, et al. Triple
negative breast cancer : Key role of Tumor-Associated Macrophages in regulating
the activity of anti-PD-1/PD-L1 agents. Biochim Biophys Acta, Rev Cancer 2018;
1869:78–84.
[60] Mckelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and
the immune response in cancer. Mamm Genome 2018;29(11–12):843–65.
[61] Russo M, Mcgavern DB. Immune Surveillance of the CNS following Infection and
Injury. Trends Immunol 2016;36(10):637–50.
[62] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in
the initiation and promotion of malignant disease. Cancer Cell 2005;7(3):211–7.
[63] Atri C, Guerfali FZ, Laouini D. Role of Human Macrophage Polarization in
Inflammation during Infectious Diseases. Int J Mol Sci 2018;19(6):1801.
[64] Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia:
The good, the bad, and the inflamed. J Neuroinflammation 2014;11:98.
[65] Khansari N, Shakiba Y, Mahmoudi M. Chronic Inflammation and Oxidative Stress
as a Major Cause of Age- Related Diseases and Cancer. Recent Pat Inflamm Allergy
Drug Discov 2009;3(1):73–80.
[66] Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of
the Cytokine Storm. Microbiol Mol Biol Rev 2012;76(1):16–32.
[67] Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration:
Leukocyte recruitment via the choroid plexus. EMBO J 2014;33(1):7–22.
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